Search Results

restor3d, Inc. and Conformis, Inc. announced that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023.

On September 5, 2023, restor3d, Inc. finalized its previously announced acquisition of Conformis, Inc. With this merger complete, there is tremendous opportunity to deliver clinically differentiated and cost-effective solutions across the orthopaedic landscape.

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the second quarter ended June 30, 2023.

Conformis, Inc. announced that leading independent proxy advisory firm, Institutional Shareholder Services Inc., has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d.

restor3d, Inc. and Conformis, Inc. announced that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approximate 96 percent premium to the closing price of Conformis stock on June 22, 2023.

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the first quarter ended March 31, 2023.

Conformis, Inc. announced that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market on Nov 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from Nov 10, 2022 to Nov 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550 and the minimum bid price deficiency matter previously disclosed by Conformis is now closed.

Conformis, Inc., an orthopedic medical device company that features personalized knee and hip replacement products, announced that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences.

Conformis, Inc., a leading medical device company that features personalized knee and hip replacement products, announced it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023.

Conformis, Inc. an orthopedic medical device company that features personalized knee and hip replacement products, announced financial results for the fourth quarter and year ended December 31, 2022.